The zebrafish has been used as a developmental and embryological model since 1930, because of its rapid organogenesis (the embryos grow rapidly and develop all their main organs within a 2-day period) and the transparency of its embryos, it is a powerful model for in vivo studies. In addition, zebrafish contain orthologs for 86% of therapeutic targets and 70% of human genes. Mutagenesis strategies have generated zebrafish models for a wide variety of human diseases. This enables an extremely fast in vivo screening process. Our facility is AAALAC accredited (housing capacity 10,000 zebrafish)
The imaging platform
AZELEAD has developed a state-of-the-art microscopy methodology, its own microscopy system and algorithms for real-time analysis of the behavior and functionality of each cell population and tissue.
Our P2 platform offers numerous infectious disease models for in vivo studies (staphylococcus, Escherichia coli…). AZELEAD offers an innovative tool for isolating new antibiotics based on a collaborative programme (Nimes University Hospital, the national diabetic foot clinic reference and the CNRS).
Our P3 platform offers several pathogen/host models for in vivo studies. We work in partnership with the BSL3 animal facilities of the University of Montpellier and Cemipai. These combinations represent a complete research and development preclinical value chain, starting from drug R&D and ending downstream of human clinical trial phases.
AZELEAD offers a unique methodology for analyzing the fate of cancer cells in patients and predicting the effectiveness of treatments in personalized medicine.